Dr. Culver is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
663 Springfield Ave
Apt 325
Berkeley Heights, NJ 07922Phone+1 215-630-9340
Education & Training
- NIH Clinical CenterPost-Doctoral Fellowship, 1987 - 1990
- University of California (San Francisco) School of MedicineFellowship, Allergy and Immunology, 1985 - 1987
- University of California (San Francisco)Chief Residency, Pediatrics, 1984 - 1985
- University of California (San Francisco)Residency, Pediatrics, 1982 - 1984
- University of California (San Francisco)Internship, Pediatrics, 1981 - 1982
- University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1981
- Drake UniversityB.A., Biology, 1973 - 1977
- Hoover High SchoolDiploma, High School, 1970 - 1973
Certifications & Licensure
- CA State Medical License 1982 - Present
- NJ State Medical License 2000 - 2025
- MD State Medical License 1987 - 2000
- IA State Medical License 1992 - 1997
- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Innovation Award Novartis Oncology, 2012
- One3 Competitiveness Award for the Oncology Franchise Novartis Oncology, 2012
- "DO" Award Novartis Oncology, 2005
- Join now to see all
Publications & Presentations
PubMed
- 124 citationsEconomic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analyt...Nathan A. Pennell, Alex Mutebi, Zheng-Yi Zhou, Marie Louise Ricculli, Wenxi Tang
JCO Precision Oncology. 2019-05-16 - 9 citationsTreatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective...Anand A. Dalal, Annie Guerin, Alex Mutebi, Kenneth W. Culver
Journal of Drug Assessment. 2018-03-12 - 5 citationsMonitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.Edmond Bendaly, Anand A. Dalal, Kenneth W. Culver, Philip Galebach, Iryna Bocharova
Advances in Therapy. 2017-06-03
Journal Articles
- Terminology for sample collection in clinical genetic studiesSpear BB, Heath-Chiozzi ME, Barnes DM, Cheeseman K, Shaw P, Campbell DA, McCarthy A, Ray SC, Culver K, McHale D Anderson DC, Dahlstroem C, Hashimoto L and Sandbrink R ..., The Pharmacogenomics Journal, 1/1/2001
- Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous g...Prados MD, McDermott M, Chang SM, Wilson CB, Fick J, Culver KW, Van Gilder J, Keles GE, Spence A and Berger M, J Neuro-Oncol, 1/1/2003
- Model organisms and new tools: choose your weapons wiselyEcker DJ, McAlpine J and Culver K, Curr Opin Drug Discov Devel, 1/1/2003
- Join now to see all
Books/Book Chapters
Press Mentions
- Five Year Follow-up Data of Pfizer’s CROWN Trial Shows Prolonged Progression-Free Survival in ALK-Positive Advanced Lung CancerJune 4th, 2024
- Pfizer’s LORBRENA Wows in Long-Term ALK-Positive Lung Cancer StudyJune 4th, 2024
Committees
- Member, Genomics, Robotics and Nanotechnology seminar held by the AAAS Program of Dialogue on Science, Ethics, and Religion (San Francisco, CA) 2001 - 2001
- Member, Design committee for the Presbyterian Church (USA) Conference on Science and Religion (Pittsburgh, PA) 1999 - 1999
- Member, AAAS Human Germ-line Interventions Working group on Scientific Freedom & Responsibility Issues (Washington D.C.) 1998 - 1998
Professional Memberships
- Member
- Member
- Member
- Member
External Links
- Foundation for Peacehttp://www.foundationforpeace.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: